I know we're getting off topic but this is interesting-- so you no longer take pita or eze? Because I take both. I'd like to hear
@Ghoul thoughts because I think he's the one that got a lot of us on the pita+ eze train haha
Ghouls apprentice here:
"There are two types of statins either lipophilic like atorvastatin and simvastatin or hydrophilic like rosuvastatin.
24 Hydrophilic statins are less cross‐plasma membrane so they have less pleiotropic effects compared to lipophilic statins.
24 Of note, statins are also classified according to their nature, either natural like simvastatin and lovastatin, or synthetic like rosuvastatin.
24 Natural and synthetic statins have different pharmacokinetic properties but they have similar lipid‐lowering effects. Remarkably, statins lead to a dose‐dependent effect in reducing cholesterol and LDL.
25"
Source:
Pros and cons for statins use and risk of Parkinson's disease: An updated perspective - PMC
Newever statins don't generally cross the blood brain barrier, and have been shown to reduce Parkinson's Disease by lowering inflammation.
Conclusion of above study:
"PD is the second most common NBD consequent to AD. Statins are the most common lipid‐lowering agents used in the management of dyslipidemia and the prevention of primary and secondary CVD events. Statins are not used in the management of PD, but they are frequently used in the cardiovascular disorders commonly associated with PD in the elderly population. Therefore, the use of statins in that population may affect PD outcomes. Statins have many pleiotropic effects like antioxidant and anti‐inflammatory effects. The possible effects of statins on PD neuropathology are conflicting either protective or harmful on PD neuropathology. As well, there is a controversial point regarding the role of serum lipids in the pathogenesis of PD. In this bargain, as statins reduce serum cholesterol, they may affect the PD neuropathology in bidirectional ways either protective or harmful. The protective role of statins against PD risk is through modulation of inflammatory, lysosomal signaling pathways, and microglia activation. However, long‐term statins therapy for primary or secondary prevention of CVDs may increase PD risk by different mechanisms including reduction of CoQ10. Taken together, according to the recent and updated studies, controversial points still present regarding the short‐ and long‐term effects of statins on PD neuropathology. Therefore, large‐scale prospective and retrospective studies are warranted in this regard to confirm the mechanistic role of statins in PD neuropathology."
Oh, I thought Repatha was a statin.
What statins do you suggest I look into? Any better than the others?
As someone in the misfortunate 1% who had side effects from older statins, Pitavastatin, the latest generation of statin that only recently went from $500/mo to a cheap generic, is the one I recommend. It was formerly limited to people who desperately needed a statin but had side effects on others. It takes the already low risk of sides from modern statins and drops it even lower.
The minuscule doses compared to others hint at how tightly focused it is. That said. most...
